Astellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...

The aggressiveness of a cancer is based on several factors, including the tumor's grade and stage, and the cells' genetic ...

Doctors examine a tumor in several different ways to determine whether a cancer is aggressive – and what kinds of treatments, if any, might work best.

Black health experts discuss how clinical trials can help mitigate Black disease and reduce cancer to a chronic illness.

A full house was in Croke Park on Wednesday, May 14 for the inaugural All-Island Cancer Summit, which marked its presence ...

Henry Butler is a prostate cancer survivor going on five years. He opens up about what recovery was like and how this journey ...

Donn Young is the former director of the Ohio State University Comprehensive Cancer Center Biostatistics Unit where he spent ...

The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to ...

Here’s what you should know about PSA screening, why medical guidelines vary and why individualized approaches are essential ...

Ed Burgess, diagnosed with stage IV prostate cancer, shares his journey of survival thanks to a combination of hormone therapy and the drug enzalutamide, highlighting the personal impact of research ...

For more than 30 years, Suzy Lawrence has been a steadfast advocate for people impacted by cancer. Her journey with the ...